Tetracaine
| Clinical data | |
|---|---|
| Trade names | Pontocaine, Ametop, Dicaine, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682640 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 75.6 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.002.106 |
| Chemical and physical data | |
| Formula | C15H24N2O2 |
| Molar mass | 264.369 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tetracaine, also known as amethocaine, is an ester local anesthetic used to numb the eyes, nose, or throat. It may also be applied to the skin before starting intravenous therapy to decrease pain from the procedure. Typically it is applied as a liquid to the area. Onset of effects when used in the eyes is within 30 seconds and last for less than 15 minutes.
Common side effects include a brief period of burning at the site of use. Allergic reactions may uncommonly occur. Long-term use is generally not recommended as it may slow healing of the eye. It is unclear if use during pregnancy is safe for the baby. Tetracaine is in the ester-type local anesthetic family of medications. It works by blocking the sending of nerve impulses.
Tetracaine was patented in 1930 and came into medical use in 1941. It is on the World Health Organization's List of Essential Medicines